	Recent patents in dr		•		.
Patent #	Subject	Assignee	Inventor(s)	Priority application date	Publication date
WO 200164164	A method for producing a nanocapsule by condensing a bioactive component in an aqueous composition, dispersing surfactant molecules into the composition, and coating the surfactant micelles with a biocompatible polymer; useful for targeted drug delivery of chemotherapeutic agents or antisense DNA, antigen delivery to antigen-presenting cells, ocular delivery of ribozymes to retinal cells, transdermal delivery of protein antibodies, or transtympanic membrane delivery of peptide nucleic acids.	GeneSegues (Chaska, MN)	Unger GM	2/28/2000	9/7/2001
WO 200158506	A device for delivering a predetermined drug dose, such as a skin patch for delivering a drug dose to the subcutaneous region of an individual; comprises a reservoir having a drug—liquid preparation, a drug delivery element, and a drug delivery mechanism.	Power Paper Ltd. (Einat, Israel)	Nitzan Z	2/10/2000	8/16/2001
WO 200158424	Multiparticulate drug compositions with an enteric coating, which prevents drug release in the stomach; useful for delivery of drugs to the small intestine.	West Pharma- ceutical Services (Lionville, PA)	Bond JR, Lafferty WCI, Smith A, Watts PJ	4/20/2000	8/16/2001
WO 200156546	A composition for treating a biological tissue responsive to an applied magnetic field, for example, a tumor; comprises several magnetoliposomes, each containing a vesicle formed of a lipid wall, superparamagnetic particles, and an inactive prodrug.	Florida St. Univ. Research Foundation (Tallahassee, FL)	Babincova M, Babinec P, Leszczynska D, Leszczynski J	2/5/2000	8/9/2001
US 20010012522	A composition for a gas-filled microparticle having a diameter of 1–10 μm comprising an outer layer of biologically compatible material and an inner layer containing a biodegradable polymer; useful for the delivery of drugs into the bloodstream.	Ottoboni TB; Short RE; Yamamoto RK	Ottoboni TB, Short RE, Yamamoto RK	4/30/1998	8/9/2001
US 6261601	A new tablet formulation for the controlled release of cipro- floxacin in the stomach, comprising ciprofloxacin, sodium alginate, xanthan gum, sodium bicarbonate, and crosslinked polyvinylpyrrolidone; provides increased gastric residence and thus increased absorption of a drug as compared with other oral-controlled drug delivery systems.	Ranbaxy Laboratories Ltd. (New Delhi, India)	Sen H, Staniforth JN, Talwar N	9/19/1997	7/17/2001
WO 200149240	A method for manufacturing porous polymer used to produce molding for use as biomedical devices, medical implants, and materials for the attachment and growth of human or animal cells.	Novartis (Basel)	Domschke AM, Francis VM	1/5/2000	7/12/2001
WO 200149311	A formulation comprising a compound having hydrogen-bonding sites blended with a first polymer and a second polymer, forming degradation products releasing the compound from the first polymer; useful as a drug delivery system for the pulsatile delivery of the active compound to a patient as well as for hormonal-based drug delivery.	Rutgers University (New Brunswick, NJ)	Kohn JB; Schachter DM	12/31/1999	7/12/2001
WO 200145742	A composition for a liquid biodegradable block copolymer capable of forming a physiologically active substance-containing implant in a living body; useful as a drug delivery system for growth hormones, antibacterial agents, anticancer or antiinflammatory agents, etc.	Samyang Corp. (Seoul, Korea)	Choi I, Seo M	12/22/1999	6/28/2001
US 6252032	An ultraviolet-absorbing polymer comprising a reaction mixture of diisocyanate, diol and/or diamine, and polyfunctional UV-absorbing monomer; useful in the production of thin film sensors, drug delivery tubing, <i>in situ</i> curable implantable materials such as bioadhesives, and nonadhesion coatings.	MiniMed (Northridge, CA)	van Antwerp WP, Yao L	7/7/1999	6/26/2001

Source: Derwent Information, Alexandria, VA. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke Street, Suite 250, Alexandria, VA 22314. Tel: 1 (800) DERWENT (info@derwent.com).